PT - JOURNAL ARTICLE AU - TAKAYUKI ANDO AU - AKIRA UEDA AU - KOHEI OGAWA AU - IORI MOTOO AU - SHINYA KAJIURA AU - TAKAHIKO NAKAJIMA AU - KATSUHISA HIRANO AU - TOMOYUKI OKUMURA AU - KENICHIRO TSUKADA AU - TAKUO HARA AU - NOBUHIRO SUZUKI AU - NAOKATSU NAKADA AU - NAOKI HORIKAWA AU - TSUTOMU FUJII AU - ICHIRO YASUDA TI - Prognosis of Immune-related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis AID - 10.21873/invivo.12281 DP - 2021 Jan 01 TA - In Vivo PG - 475--482 VI - 35 IP - 1 4099 - http://iv.iiarjournals.org/content/35/1/475.short 4100 - http://iv.iiarjournals.org/content/35/1/475.full SO - In Vivo2021 Jan 01; 35 AB - Background: Immune-checkpoint inhibitors (ICI), including nivolumab and pembrolizumab, are among the standard treatments for previously treated advanced gastric cancer (AGC). This study aimed to evaluate the frequency of immune-related adverse events (irAEs) and the correlation between irAEs and their efficacy in AGC cases. Patients and Methods: Patients were divided into two groups according to irAE occurrence. The frequency of irAEs and the treatment outcome (response rate [RR], progression-free survival [PFS], and overall survival [OS]) were evaluated. The survival rates were evaluated by landmark analysis considering lead-time bias. Results: Among 108 patients who received nivolumab or pembrolizumab, 17 (15.7%) had irAEs. In a 4-week landmark analysis, the RR, median PFS, and median OS were 28.5%, 3.9 months (95% CI=2.8-9.3), and 12.2 months (95% CI=3.8-NA) in patients with irAEs, while 3.0% (2/65), 1.8 months (95% CI=1.4-2.1), and 3.5 months (95% CI, 2.9-5.1) in patients without irAEs, respectively. In multivariate analysis, irAEs were associated with better PFS (HR=2.08, 95% CI=1.34-3.21). Conclusion: The occurrence of irAEs was associated with a better clinical outcome of ICIs in patients with AGC.